Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
59
LGND Quote, Financials, Valuation and Earnings
Last price:
$200.42
Seasonality move
:
10.32%
Day range:
$197.81 - $202.50
52-week range:
$93.58 - $212.49
Dividend yield:
0%
P/E ratio:
96.42x
P/S ratio:
15.69x
P/B ratio:
4.15x
Volume:
427.4K
Avg. volume:
237.3K
1-year change:
75.81%
Market cap:
$3.9B
Revenue:
$167.1M
EPS (TTM):
$2.08
Analysts' Opinion
-
Consensus RatingLigand Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $243.44, Ligand Pharmaceuticals, Inc. has an estimated upside of 21.52% from its current price of $200.33.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $220.00 representing -9.82% downside risk from its current price of $200.33.
Fair Value
-
According to the consensus of 6 analysts, Ligand Pharmaceuticals, Inc. has 21.52% upside to fair value with a price target of $243.44 per share.
LGND vs. S&P 500
-
Over the past 5 trading days, Ligand Pharmaceuticals, Inc. has overperformed the S&P 500 by 5.58% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Ligand Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ligand Pharmaceuticals, Inc. has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Ligand Pharmaceuticals, Inc. reported revenues of $115.5M.
Earnings Growth
-
Ligand Pharmaceuticals, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Ligand Pharmaceuticals, Inc. reported earnings per share of $5.68.
Enterprise value:
3.7B
EV / Invested capital:
--
Price / LTM sales:
15.69x
EV / EBIT:
129.28x
EV / Revenue:
14.84x
PEG ratio (5yr expected):
0.23x
EV / Free cash flow:
182.54x
Price / Operating cash flow:
192.98x
Enterprise value / EBITDA:
57.30x
Gross Profit (TTM):
$204M
Return On Assets:
4.65%
Net Income Margin (TTM):
19.34%
Return On Equity:
5.72%
Return On Invested Capital:
5.15%
Operating Margin:
46.85%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $153.6M | $152.4M | $251.2M | $51.8M | $115.5M | |
| Gross Profit | $90.2M | $109.5M | $204M | $41.1M | $103.6M | |
| Operating Income | -$6.9M | $18M | $28.8M | $11M | $54.1M | |
| EBITDA | $31.1M | $55.6M | $65.1M | $20.5M | $62.8M | |
| Diluted EPS | $0.84 | $2.51 | $2.08 | -$0.39 | $5.68 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $432.1M | $220.4M | $254M | $309.4M | $753.9M | |
| Total Assets | $1.3B | $1.1B | $769.2M | $954.9M | $1.5B | |
| Current Liabilities | $36.3M | $135.2M | $15.7M | $24.8M | $30.5M | |
| Total Liabilities | $461.6M | $234.3M | $101.3M | $113.7M | $526.6M | |
| Total Equity | $812.1M | $816.3M | $667.9M | $841.2M | $950.2M | |
| Total Debt | $328.4M | $111.5M | $5.8M | $6.3M | $449.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $95M | $75.4M | $31.8M | $36.3M | $13.2M | |
| Cash From Investing | -$8.7M | -$115.3M | -$397.8M | -$46.5M | -$353.4M | |
| Cash From Financing | -$70.6M | $83.3M | $440.4M | $55.3M | $409.6M | |
| Free Cash Flow | $89.7M | $5.7M | $20.4M | $22.1M | $4.8M | |
LGND
Sector
Market Cap
$3.9B
$27.9M
Price % of 52-Week High
94.28%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-6.77%
-1.49%
1-Year Price Total Return
75.81%
-16.66%
Beta (5-Year)
1.026
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$191.96
200-day SMA
Buy
Level
$144.60
Bollinger Bands (100)
Buy
Level
158.61 - 196.85
Chaikin Money Flow
Buy
Level
7.4M
20-day SMA
Buy
Level
$194.18
Relative Strength Index (RSI14)
Buy
Level
59.11
ADX Line
Buy
Level
18.21
Williams %R
Sell
Level
-9.4967
50-day SMA
Buy
Level
$193.24
MACD (12, 26)
Buy
Level
0.02
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
23M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (12.4078)
Buy
CA Score
(Annual)
Level (1.501)
Buy
Beneish M-Score
(Annual)
Level (-3.0801)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-10.1735)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.
Stock Forecast FAQ
In the current month, LGND has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The LGND average analyst price target in the past 3 months is $243.44.
-
Where Will Ligand Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ligand Pharmaceuticals, Inc. share price will rise to $243.44 per share over the next 12 months.
-
What Do Analysts Say About Ligand Pharmaceuticals, Inc.?
Analysts are divided on their view about Ligand Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ligand Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $220.00.
-
What Is Ligand Pharmaceuticals, Inc.'s Price Target?
The price target for Ligand Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $243.44 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is LGND A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ligand Pharmaceuticals, Inc. is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LGND?
You can purchase shares of Ligand Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ligand Pharmaceuticals, Inc. shares.
-
What Is The Ligand Pharmaceuticals, Inc. Share Price Today?
Ligand Pharmaceuticals, Inc. was last trading at $200.42 per share. This represents the most recent stock quote for Ligand Pharmaceuticals, Inc.. Yesterday, Ligand Pharmaceuticals, Inc. closed at $200.33 per share.
-
How To Buy Ligand Pharmaceuticals, Inc. Stock Online?
In order to purchase Ligand Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get LGND Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
LGND
Sector
P/E ratio
96.42x
23.85x
PEG ratio
0.23x
-0.01x
P/B ratio
4.15x
1.81x
Price / LTM sales
15.69x
1.58x
Growth Metrics
LGND
Sector
Revenue growth
122.85%
4.62%
Earnings growth
1559.91%
10.5%
Revenue (5-year growth)
6.8%
6.5%
Earnings forecast
$1.82
-$0.21
Profitability
LGND
Sector
Profitability FY 2024
$120.8M
$3.6M
Return on invested capital
5.15%
-31.87%
Return on assets
4.65%
-28.18%
Return on equity
5.72%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
5
Balance Sheet
LGND
Sector
Total cash
$664.5M
$26.4M
Short term investments
$183.9M
$25.7M
Total assets
$941.8M
$76.9M
Long term debt
$449.9M
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
